SCHEMBL6634545

SCHEMBL6634545

CCOC(=O)C1CCC(N2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
TSHR P16473 1/20 0.51
CHRM1 P11229 2/20 0.48
MAPT P10636 2/20 0.46
TDP1 Q9NUW8 2/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.44
GAA P10253 2/20 0.43
HTT P42858 1/20 0.43
ALOX12 P18054 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.42
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25030105 1.00 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1TSHRCHRM1
SCHEMBL9408055 0.90 CHRM1 (0.61) ALDH1A1KMT2AMEN1TSHRCHRM1
SCHEMBL30234208 0.88 TDP1 (0.51) ALDH1A1KMT2AMEN1TSHRCHRM1
SCHEMBL25030529 0.88 TDP1 (0.51) ALDH1A1KMT2AMEN1TSHRCHRM1
SCHEMBL337418 0.86 ALDH1A1 (0.65) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL22557474 0.85 HPGD (0.47) ALDH1A1KMT2ACHRM1MAPTHPGD
SCHEMBL63877 0.84 USP2 (0.53) ALDH1A1CHRM1MAPTHPGDHTT
SCHEMBL2543712 0.84 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1TSHRCHRM1
SCHEMBL20066231 0.84 CHRM1 (0.53) ALDH1A1KMT2AMEN1TSHRCHRM1
SCHEMBL6643493 0.84 ALDH1A1 (0.60) ALDH1A1KMT2AMEN1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-02-12 US disclosed
US-12521393-B2 Cytotoxicity targeting chimeras for CCR2-expressing cells GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-13 US disclosed
EP-4640280-A2 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-10-29 EP disclosed
EP-4384223-B1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-10-01 EP disclosed
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-05-01 US disclosed
US-20240325392-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-10-03 US disclosed
EP-4384224-A1 CYTOTOXICITY TARGETING CHIMERAS GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-06-19 EP disclosed
WO-2023017483-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 WO disclosed
WO-2023017484-A1 CYTOTOXICITY TARGETING CHIMERAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 WO disclosed
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
EP-1465867-A1 LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO Neurocrine Biosciences, Inc. (US) 2004-10-13 EP disclosed
WO-2003031410-A1 LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 ALDH1A1 1627/4885KMT2A 1711/4885MEN1 4141/4885
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS HAVCR2, CD47, CYTH3 ALDH1A1 4788/4885KMT2A 3960/4885MEN1 3723/4885
US-20240325392-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 ALDH1A1 4466/4885KMT2A 3923/4885MEN1 4270/4885
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto GPR119, GLP1R, SLC5A2 ALDH1A1 1526/4885KMT2A 1530/4885MEN1 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.